LUND, Sweden, Nov. 5, 2021 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a diagnostic company that develops and sells
highly accurate blood tests for the early detection of cancer,
today announced that its CEO, Patrik
Dahlen, will present and participate at the Jefferies London
Healthcare Conference in London,
UK, on November
16th 2021, and invited investors to participate
by webcast.
Event Details:
Jefferies London Healthcare Conference
Tuesday, November 16, 2021
Immunovia Presentation at6:40 pm
CET
A webcast of the presentation will be available via the
following link:
https://wsw.com/webcast/jeff201/immnov/2169972
The webcast will also be archived shortly afterwards under
"Presentations" in the Investors section of the Company's website
at www.immunovia.com and be available for approximately 30
days.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
2021.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-present-at-jefferies-london-healthcare-conference,c3448178
The following files are available for download:
https://mb.cision.com/Main/13121/3448178/1492132.pdf
|
Press release
(PDF)
|